Covidien Completes Previously Announced Transactions

Covidien Ltd. (NYSE: COV, BSX: COV) today announced that one of its

subsidiaries has acquired 100% ownership of Tissue Science Laboratories

a medical device company dedicated to the research, development and

commercialization of tissue implant products for surgical and wound care

therapies. Covidien launched a public tender offer in the United Kingdom

for all of Tissue Science Laboratories outstanding shares held by UK

residents on March 12, 2008. Covidien has also completed the sale of its European Incontinence

business to a private French company who will rename the business Lille

Healthcare. Terms of the agreement were not disclosed. The business

which is headquartered in Lille, France, was formerly part of Covidien´s

Medical Supplies segment and had sales of $109 million in fiscal 2007. ABOUT COVIDIEN LTD. Covidien is a leading global healthcare products company that creates

innovative medical solutions for better patient outcomes and delivers

value through clinical leadership and excellence. Covidien manufactures

distributes and services a diverse range of industry–leading product

lines in four segments: Medical Devices, Imaging Solutions

Pharmaceutical Products and Medical Supplies. With 2007 revenue of

nearly $9 billion, Covidien has more than 42,000 employees worldwide in

57 countries, and its products are sold in over 130 countries. Please

visit www.covidien.com to learn

more about our business.